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Mitochondrial Complex II (succinate:ubiquinone oxidoreductase) is purified in a partially inactivated state, which can be activated by removal
of tightly bound oxaloacetate (E.B. Kearney, et al., Biochem. Biophys. Res. Commun. 49 1115–1121). We crystallized Complex II in the presence
of oxaloacetate or with the endogenous inhibitor bound. The structure showed a ligand essentially identical to the “malate-like intermediate” found
in Shewanella Flavocytochrome c crystallized with fumarate (P. Taylor, et al., Nat. Struct. Biol. 6 1108–1112) Crystallization of Complex II in the
presence of excess fumarate also gave the malate-like intermediate or a mixture of that and fumarate at the active site. In order to more
conveniently monitor the occupation state of the dicarboxylate site, we are developing a library of UV/Vis spectral effects induced by binding
different ligands to the site. Treatment with fumarate results in rapid development of the fumarate difference spectrum and then a very slow
conversion into a species spectrally similar to the OAA-liganded complex. Complex II is known to be capable of oxidizing malate to the enol form
of oxaloacetate (Y.O. Belikova, et al., Biochim. Biophys. Acta 936 1–9). The observations above suggest it may also be capable of interconverting
fumarate and malate. It may be useful for understanding the mechanism and regulation of the enzyme to identify the malate-like intermediate and
its pathway of formation from oxaloacetate or fumarate.
© 2006 Elsevier B.V. All rights reserved.Keywords: Membrane protein; Protein crystallography; X-ray structure; Electron transport; Redox enzyme; Succinate dehydrogenase1. Introduction
Complex II catalyzes one step of the Krebs tricarboxylic acid
cycle, oxidation of succinate to fumarate. This step is unique,
among the oxidative steps of the Krebs cycle, in coupling the
oxidation to the ubiquinone pool rather than NAD/NADH, andAbbreviations: OAA, oxaloacetate; MDH, malate dehydrogenase; FCc,
flavo-cytochrome c; TEO, the “malate-like intermediate” found in 1QJD;
Complex II, succinate ubiquinone oxidoreductase; E.C. 1.3.5.1. Q1 and Q2,
ubiquinol with only 1 or two isoprenoid units in the side-chain
☆ Specific X-ray structures from this and other labs are referred to by their
PDB ID codes; literature references if not given are available in the PDB record.
The coordinates for the two structures described here have been deposited with
the PDB as 2H88 (TEO-containing structure) and 2H89 (malonate-containing
structure).
⁎ Corresponding author. Tel.: +1 510 486 4335.
E-mail address: EABerry@LBL.gov (E.A. Berry).
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doi:10.1016/j.bbabio.2006.06.015the reason for this is clear if one examines the redox midpoint
potentials of the Krebs cycle reactions. The succinate/fumarate
couple has a midpoint potential around +25 mv at pH 7, much
higher than that of the NADH/NAD+ couple and thus incapable
of reducing the latter under normal conditions or at a kinetically
competent rate. The other three oxidations of the Krebs cycle
have considerably more reducing power: the weakest being the
malate/oxaloacetate couple (Em7=−166 mv). Thus the unique
status of Complex II, as the only member of the Krebs cycle that
is membrane bound and part of the respiratory chain, can be
seen as an adaptation to let this weakest step of the cycle make a
smaller energetic contribution by bypassing Complex I and
coupling site 1. Presumably a pre-existing membrane-bound
quinol:fumarate reductase, which served as a terminal oxidase
in the pre-aerobic world, was recruited to perform this function
in some early aerobic organism, and has been tailored by
evolution for its new role by development of a new quinone
binding site and the “tunnel diode” effect [1] which inhibits the
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of the reaction. Covalently attachment of FAD, which raises its
potential and allows efficient oxidation of succinate [2] was an
essential step in evolution of Complex II but may have occurred
earlier as an adaptation to menaquinone oxidation, because
quinone-coupled fumarate reductases share this feature. Soluble
fumarate reductases such as flavocytochrome c (FCc, see
below) and L-aspartate oxidase have noncovalently bound FAD.
Early investigators of Complex II found that, in submito-
chondrial particles, purified Complex II, or soluble succinate
dehydrogenase preparations, the enzyme was in a relatively
inactivated state. Various seemingly unrelated treatments were
developed to bring it to a higher, constant level of activity [3].
Later it was realized that all of these treatments resulted in
removal of tightly bound oxaloacetate (OAA) in parallel with
activation of the dehydrogenase [4]. Both activation and OAA
removal show a high activation energy, proceeding at a
negligible rate at 4 °C and on a time scale of tens of minutes
at room temperature.
OAA binds as a classical competitive inhibitor, with a
dissociation constant that can be calculated from the ratio of on
and off rate constants [5]. However due to the extremely low
dissociation rate (∼ .02 min−1 [5]) it does not equilibrate on the
time-scale of the initial-rate measurements used in classic
Michaelis–Menten kinetic studies, and appears more like an
noncompetitive inhibitor on this time scale. If the SDH assay is
carried out at 20 °C or above, gradual activation of the OAA-
inhibited enzyme by succinate results in accelerating rates
during the course of the assay, making it clear that the initial rate
does not reflect the full activity of the enzyme.
The physiological significance of this inhibition by OAA is
not clear (at least to the present authors), however it is to be
noted that OAA is the end product and the initial substrate of the
Krebs cycle, and would be expected to accumulate under
conditions where the supply of reduced two-carbon units to
acetyl CoA from glycolysis or fatty acid metabolism is
interrupted. This may be prevented by its extremely low Kd
inhibition of Complex II, involved in its production. The
competitive nature of the inhibition allows high concentration
of succinate to overcome the inhibition, however the relative
affinity of the oxidized enzyme for succinate is ∼600 times
lower than that for OAA [5].
It has been clearly shown [6–8] that in addition to oxidizing
succinate, Complex II also oxidizes D- or L-malate to (the enol
form of) OAA. While this may not seem particularly surprising
in light of the structural similarity between succinate and malate
or fumarate and enol-OAA, it raises a number of interesting
points.
First there is the question of an energetic leak: malate
oxidation is normally coupled to the NADH pool by malate
dehydrogenase (MDH). The futile cycle that would be expected
to result from simultaneous operation of both enzymes becomes
irrelevant in light of the low rate of malate oxidation by
Complex II— about 8 min−1 at best with L-malate [8], and that
under non-physiological conditions.
Another consequence of malate oxidation by Complex II,
together with the fact that the product OAA is an inhibitor withan extremely low off-rate, is that malate is a suicide inhibitor of
Complex II. The highly exergonic oxidation of malate by
ubiquinone contributes to the driving force for loading the
enzyme with OAA despite the low rate. Surprisingly, the
Complex-II-catalyzed MDH reaction runs for several turnovers
at a rate higher than the dissociation rate of tightly bound OAA.
This suggests that the form of the enzyme with tightly-bound
OAA is different from the initial product complex from malate
oxidation [8]. This seems not to be a matter of tautomerization,
as the enol form of OAAwhich is produced by malate oxidation
is the form which most rapidly inhibits succinate oxidation [8].
Crystallographic studies of Complex II have lagged behind
those of Complexes III and IV. This may seem surprising in that
the bottleneck in these studies is preparation of suitable crystals,
and it would be expected that Complex II, with a greater
proportion of mass in the water-exposed subunits 1 and 2
relative to transmembrane region (subunits 3 and 4) would be
relatively easy to crystallize. It may be that the monotopic
nature of the protein, with hydrophilic surface on only one side
of the membrane, impedes crystallization.
In 1999, the first X-ray structures became available for a
number of fumarate reductase (FRD) enzymes with dicarbox-
ylate sites homologous to that of Complex II. The FRD's of E.
coli [9] and of Wollinella succinogenes [10] have flavoprotein
and iron–protein subunits homologous to those of Complex II,
and like Complex II have membrane-anchor subunit(s) contain-
ing quinone redox sites. The quinone-oxidizing sites of the
membrane-bound FRD's is not related to the quinone reduction
site of Complex II, involving (at least in the case of the E. coli
enzyme) different ligands on different transmembrane helices
and a different section of the iron–sulfur protein. On the other
hand the flavoprotein and the dicarboxylate site are clearly
homologous.
The flavocytochrome c FRD (FCc) of Shewanella [11,12] is
a soluble protein with a single subunit and fumarate reductase
activity. Despite being coupled to a cytochrome domain instead
of an iron–sulfur protein, the dicarboxylate binding domain of
FCc is clearly homologous to that of Complex II, and was well
ordered in the crystals.
These structures provided the first clear picture of the loaded
dicarboxylate binding site. Interestingly, in one of the highest
resolution crystals, grown in the presence of fumarate, the active
site contained not fumarate but a “malate-like intermediate”
which the authors proposed was formed by slow enzymatic
hydration of fumarate by FCc [12]. It was suggested by Ackrell
[2] that the nature of this intermediate may have a bearing on the
extremely tight binding of OAA to mitochondrial Complex II.
The first structure of a “true” Complex II (i.e. succinate
ubiquinol oxidoreductase, E.C.1.3.5.1) was not the mitochon-
drial complex but that of E. coli [13]. The region around the
dicarboxylate site, whose ligand was modeled as OAA, was for
the most part similar to that in FCc, however the proposed
catalytic arginine (R286 in E. coli) was poorly ordered and was
modeled in an unusual rotamer with the guanidino group turned
away from the active site and toward Glu255. In 2005–2006,
structures became available for the porcine [14] and avian
[15,16] mitochondrial Complex II. The porcine model had no
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modeled as in the E. coli structure. However our avian structure
was striking in that the dicarboxylate site region superimposed
very accurately on that of the Shewanella FCc, including the
malate-like ligand. For purposes of discussion in this paper, we
refer to this “malate-like ligand” as TEO, the 3-letter ligand ID
assigned to it in the PDB. The identity of that ligand is the main
subject of ongoing studies of which this paper is a preliminary
report.
The possibility that the same “malate-like intermediate”
TEO can be obtained starting from fumarate or OAA (and
presumably from succinate or malate), and the implications
for the catalytic capabilities of the site, are intriguing. Now
we have refined a higher-resolution structure (2H88,
including data up to 1.74 Å) to obtain an accurate model
of the ligand for identification and comparison with that
obtained from fumarate in FCc. We also present here the
structure of the malonate-bound complex (2H89). Attempts
to prepare the fumarate-bound complex resulted in the
malate-like intermediate or a mixture of that and fumarate.
In addition, we are studying the UV-visible spectral changes
in the enzyme occurring upon binding of different ligands,
including slow changes taking place after binding, to
monitor the contents of the site. Preliminary basis spectra
from these studies are presented here.
2. Materials and methods
Chicken Complex II was purified and crystallized as described [15]. The
enzyme concentration was determined from the dithionite-reduced spectrum
using the approximate extinction coefficient of 16.8 mM−1 at 560–542 for the
reduced protein [15]. Routinely no attempt was made to adjust the redox state or
remove endogenous OAA, and the crystal structure as well as spectral
experiments to be described below show that the dicarboxylate site is occupied.
Protein purification and crystal growth were carried out at 4 °C where the rate of
OAA dissociation is extremely slow, however the crystallization setups were
done at room temperature, taking about 10 min per tray.
Within either crystal form, crystals were quite isomorphous. This permitted
new structures to be solved by rigid-body refinement of the best previous
structure of that form against the new data, followed by introduction of any new
ligand, and B-factor and positional refinement interspersed with examination
and manual rebuilding. In the case of the type 2 (P21, pseudo-orthorhombic)
crystals, it was necessary to make a consistent choice of two non-equivalent
possibilities for indexing in order for rigid-body refinement to work, as the
lattice has higher symmetry than the unit cell contents.
The malonate-loaded crystal was obtained by co-crystallization: 200 μl of
0.42 mM Complex II (in 20 mM Tris–HCl pH 7.5, 0.5 mM EDTA, and 10 g/L
octyl glucoside) was treated with 2 μl of 0.1 M disodium malonate for a final
concentration of 1 mM and stoichiometric ratio of 2.4 to 1. Then 15 μl aliquots
of this were mixed with 15 μl of the precipitant and 1 μl of the additive described
[15] to give final concentrations of 0.21 mM protein, 10 g/l (34 mM) octyl
glucoside, 50 mM HEPES pH 7.5, 10 mM Tris–HCl pH 7.5, 1.3 mM MgCl2,
1.6 mM MnCl2, 50 g/l PEG 3350, 15 ml/L PEG 400, 25 ml/L isopropanol,
1.5 mM NaN3, and 0.25 mM EDTA; and equilibrated against the precipitant by
vapor diffusion in the sitting drop format. One of the resulting type 1 crystals
was used to collect a dataset to 2.4 Å on beamline 5.0.2 at the Advanced Light
Source (ALS), Berkeley CA.
The highest resolution structure containing TEO was obtained in an
unsuccessful attempt to ensure complete replacement of the endogenous OAA
by fumarate. A two-step exchange was carried out: First the protein was treated
with 2 mM malonate at room temperature for about 3 h to displace OAA, then it
was centrifuged through a glycerol density gradient, as in the purification
procedure [15] except that the gradient contained 5 mM fumarate. The gradientwas fractionated, fractions containing Complex II were pooled, and a sample
was saved at this stage for spectral analysis. A portion of the remainder was
concentrated and exchanged into the usual buffer for crystallization, except that
5 mM fumarate was present. Crystallization was as above. Type 1 crystals
formed and some were frozen 30 days after setup. A diffraction data set was
collected and the structure solved to 2.4 Å from one of these. Later type 2
crystals formed, apparently at the expense of the type 1 crystals, in most of the
wells. As part of another experiment, some of the wells were treated with short-
chain ubiquinone analogs Q1 or Q2 on day 49. It was not noted at the time, but
presumably type 2 crystals were already present at this time. Type 2 crystals
were frozen at day 54 and 61 after setup, and three of these yielded high
resolution (<2.0 Å) datasets. The one selected for refinement and deposition to
illustrate the TEO ligand (as 2H88) was from a well treated with Q2, however
there is no indication from density at the Q site that Q2 bound there. The dataset
was collected at beamline 5.0.2 at the ALS.
UV-Visible spectra were recorded with an Aminco DW2 dual wavelength
spectrophotometer, refurbished and equipped for acquisition of digital spectra
by OLIS Inc., operated in single wavelength, split beam mode. Preliminary
standard reference spectra for the unliganded enzyme and for the spectral
changes induced by OAA, fumarate, malonate, and 3-nitropropionic acid were
obtained as described in Results. Experimental spectra were fit to a linear
combination of basis spectra as described [17], using wavelength points at 0.1 or
0.2 nm intervals in the range 360–700 nm. In order to allow for baseline drift,
two additional spectra consisting of a constant offset and a slanted line were
always included in the fitting basis set. In some cases the derivative of the
unliganded enzyme spectrum was also included to allow a first-order Taylor's-
series correction for slight wavelength miscalibration.
To see the temperature dependence of the OAA dissociation, the cuvet
chamber was warmed or chilled with circulating water from a thermostatted
water bath. The temperature recorded was that in the water bath, and it is
possible that the cuvet reached a temperature a few degrees less extreme at the
hottest and coldest temperatures, so this preliminary experiment should not be
taken as an accurate determination of the activation energy but rather as
evidence for a large temperature dependence.
For recording spectra, Complex II was diluted in a buffer (Buffer A)
consisting of 20 mM Na-MOPS pH 7.5, 100 mM NaCl, 0.5 mM Na-EDTA, and
0.1 g/L dodecyl maltoside; supplemented as indicated. Glutamic-oxalacetic
transaminase was Type 1, Ammonium Sulfate suspension, from Sigma-Aldrich
Research. L-glutamate, L-aspartate, L-malate, fumarate, succinate, and malonate
were also obtained from Sigma-Aldrich Research. Other chemicals were
obtained from the same source or from Amresco.
3. Results
3.1. A high-resolution structure of the “malate-like
intermediate”
As reported [16] crystals of avian Complex II from
preparations either containing the endogenous inhibitor or
treated with OAA both appear to have a ligand in the
dicarboxylate site identical to the “malate-like intermediate”
TEO seen in high-resolution structures of the Shewanella
frigidimarina Fcc FRD [12]. Now we have collected data from
two TEO-containing crystals diffracting to 1.7 Å, although due
to constraints of detector geometry the data is complete to only
1.9 Å. The structure has now been refined to a Free R-factor of
20.9 (Table 1) against one of these datasets and is being
deposited in the PDB with ID (2H88).
A stereo illustration of the overall structure is shown in the
upper panel of Fig. 1, made with coordinates from 2H88. The
head group of ubiquinone, which appears not to be present in
2H88, was modeled in for the purpose of this illustration based
on structures 1NEK (E. coli Complex II [13]) and on the binding
of carboxin in structure 2FBW [16].
Table 1
Data processing and refinement statistics for structure 2H88, with TEO at the
active site, and 2H89, with malonate
PDB ID code 2H88 2H89
Ligand modeled TEOa malonate
Space group P21 P212121
Cell parameters 120.1 199.4 68.0 90 90.00 90 70.5 84.0 291.6 90 90 90
Resolution range 45–1.74 Å 50.68–2.4 Å
(last shell) (1.70–1.74) (2.40–2.46)
Completeness 87.0% (38.8%) 85.4% (43.8%)
# Reflections 304101 (8542) 58846 (1881)
Cryst. R value 0.181 (0.348) 0.230 (0.38)
Free R value 0.209 (0.354) 0.286 (0.44)
B values (Å2)
From Wilson plot 23.8 Å2 51.8 Å2
Mean atomic
B value
32.4 Å2 61.7 Å2
RMS deviations
from ideality (Å)
Bond lengths 0.024 Å 0.012 Å
Bond angles 2.0° 1.6°
Dihedral angles 22.7° 22.2°
Improper angles 1.30° 0.92°
a TEO-malate-like intermediate described in the Shewanella FCc active site
[12].
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the main focus of this report, is enlarged in the same orientation
in the lower panel of Fig. 1, which can be used to orient the
more detailed depictions of Figs. 3 and 4 in the overall structure.
The ligand, shown as a green space-filling model of TEO, is
sandwiched between FAD (blue ball-and-stick) and the CAP
domain of the protein, shown in magenta. The neck by which
the CAP domain is attached to the rest of the flavoprotein is a
pair of long, twisted strands (strands 1 and 2 of sheet E in the
PDB secondary structure assignment), also shown in magenta.
Histidines 253 and 364 from these strands hydrogen-bond the
ligand, as do Thr265 (from the turn between the strand E1 and
the first helix of the CAP domain) and Arg297 (from the
proximal end of the long helix α11 of the CAP domain). Arg408
from the FAD domain can also be seen H-bonding to TEO on
the upper right.
Fig. 2 shows the excellent density and clear resolution of the
irons and sulfurs in the Fe3S4 cluster of center 3, which are
separated by about 2.2 Å. In a similar map made with the model
and coordinates of 2FBW, the sulfur atoms appeared as
unresolved shoulders on the sides of the iron peaks. Complex
II contains one heme moiety (Cytochrome bII, labeled “heme”
in Fig. 1) with ligation by His98 of chain C and His46 of chain D
in the membrane anchor domain. Since there had been some
indication from previous structures [14,16] that the heme axial-
ligand bond lengths were unusually long, this distance restraint
was dropped during one cycle of refinement (not shown)
resulting in bond lengths ranging from 1.99 to 2.04; not
significantly different from 2.00 as in many other heme proteins.
Fig. 3 shows, in the top panel, a stereo view of the structure
around the dicarboxylate site, with the 2Fo–Fc electron
density map superimposed. As described at lower resolution
for structure 2FBW [16], the ligand lies flat on the plane of the
FAD isoalloxazine ring, held in place by numerous H-bonds,but with the C1 carboxylate which extends beyond the edge of
the ring twisted about 60° out of the plane of the rest of the
molecule.
The binding pocket for dicarboxylate seen in 2H88 (and other
structures with closed CAP domain) is extremely tight, with the
volume scarcely exceeding the Van-der-Waals surface of the
atoms of the ligand (not shown). There are no water molecules
directly in the pocket. The closest water to TEO is 6A away and
on the other side of the backbone N of Glu266 (the H-bonded
backbone N in the upper left corner of Fig. 2). On the other side
of the Glu266 side chain (not shown) is a string of H-bonded
waters, interacting with Arg269, Asp407, and Asn251; and in
fact most of the FP is well hydrated except the region around
TEO and the FAD isoalloxazine ring. The high-resolution
structure of Shewanella FCc E378D mutant 2B7R [18] also has
no waters in the dicarboxylate site, suggesting that if fumarate
can be hydrated to TEO as suggested [12], the process must
involve a transient, infrequent, obstructed diffusion of water into
the site to take part in the reaction. Transient opening of the CAP
domain might facilitate water entry.
The lower panel of Fig. 3 compares the dicarboxylate site of
our structure with that of that of Shewanella FCc (PDB ID
1QJD). The structures are superimposed in such a way as to
minimize the RMS deviation between the protein backbone in
highly conserved regions surrounding the active site. Although
the ligands themselves were not used in the structural
alignment, their superposition is nearly perfect, with RMS
deviations of 0.25 Å for the 9 atoms and maximum
displacement of any atom 0.37 Å.
Since the origin of the ligand in 2H88 is somewhat uncertain,
and as described below is likely to be fumarate as in the She-
wanella structure (because crystallization of the fumarate-
loaded complex was being attempted; see Materials and
methods), we also compared it with our previous structure
2FBW in which the endogenous inhibitor, presumed to be
OAA, is present. After superposing the backbones of the
flavoprotein subunits, the 18 atoms of the ligands in both
monomers superimposed with RMSD 0.21 Å. The conclusion
that the same ligand is present in all three structures seems
inescapable, that is, the tightly bound inhibitor in the OAA-
inhibited enzyme is the same as the “malate-like intermediate”
TEO visualized in fumarate-treated Shewanella FCc FRD.
During the last stages of refinement we reduced the topology
restraints for the ligand, maintaining the bond definitions to
avoid nonbonded repulsion but setting the energy terms for
bond lengths, angles, dihedrals, and impropers to zero, thus
effectively refining free atoms against the X-ray data. Non-
crystallographic positional restraints were enforced for the
atoms of the ligand, as there was no indication of or reason to
expect asymmetry between the buried ligands in the two
monomers of the non-physiological dimer present in the
asymmetric unit.
Bond lengths, angles and dihedral angles for the TEO ligand
in each monomer of the new structure and in the Shewanella
structure are given in Table 2. This not only confirms the
similarity to the FCc structure but may be useful in assigning
double vs. single bonds and sp2 vs sp3 centers, although an
Fig. 1. Overall view of Complex II, detail of dicarboxylate site. The dicarboxylate site, represented by a green space-filling model of the “malate-like ligand” found in
the oxaloacetate-inhibited complex, is in the flavoprotein subunit between the CAP domain (magenta) and the rest of the flavoprotein (yellow). The region around the
dicarboxylate site is expanded in the lower panel, and key residues involved in binding TEO are labeled. Returning to the overall structure (upper panel), a series of
three iron–sulfur clusters transfers electrons between Flavin (blue) at the dicarboxylate site and the quinone binding site (brown ubiquinone headgroup, labeled). The
coordinates are from structure 2H88, except for ubiquinone, which was modeled in for the purpose of this illustration based on structures 1NEK (E. coli Complex II)
and on the binding of carboxin in structure 2FBW.
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would require even higher resolution. Care must be taken in not
to over interpret the data. Our current analysis will be described
in Discussion.
3.2. Binding of malonate in the dicarboxylate site
In contrast to the attempt to prepare the fumarate-loaded
complex, crystallization in the presence of malonate gave the
expected result. Fig. 4 shows the dicarboxylate site of a crystalprepared from malonate-treated Complex II. The resolution
(2.4 Å, see Table 1) is not as high as the structure described
above, but the density is clearly consistent with a shorter
dicarboxylate the size of malonate. One carboxylate of
malonate is in essentially the same place as the C1 carboxylate
of TEO, bonded to Thr265 and the backbone N of Glu266. the
difference in length of the ligands thus puts the other
carboxylate somewhat short of the position of the C4
carboxylate of TEO. The difference is accommodated partly
by movement of the guanidino group of Arg408 towards the
Fig. 2. Atomic resolution for atoms of the Fe3S4 cluster in structure 2H88. The 2Fo–Fc map is contoured at 15 σ (magenta) to show the iron atoms, and at 6 σ
(cyan) to show the sulfurs as well. The irons and sulfurs, separated by about 2.2 Å, are well resolved in this structure.
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catalytic residue Arg297 interacts with this carboxylate and
with the central carbon, much as it does with TEO in the OAA-
loaded structure.Fig. 3. Stereo view of the malate-like ligand in the new high resolution structure
molecule which lies flat against the FAD isoalloxazine ring. Upper panel: the co
Fc map from that structure contoured at 1.7 σ. The view is from the direction
oxygen. Arg 297 and Arg408 are labeled. His253 can be seen H-bonding TEO
Thr265, and the backbone N of Gly62. One more H-bond from the backbone N
coordinates of 2H88 (elemental colors) are superimposed on the same region in
atoms in 8 stretches of the FAD and CAP domains of the flavoproteins (rmsd
ligands.Malonate was also observed and modeled in the
dicarboxylate site of Wolinella succinogenes crystallized in
the presence of 10 mM malonate ([19], structure 1E7P) with
the cap domain in the closed conformation. The new. Note how the C1 carboxylate is twisted out of the plane of the rest of the
ordinates from structure 2H88 (monomer 1) are shown together with a 2Fo–
of His 364 which has been removed, together with its H-bond to the C2
from the top. To the left are the backbone N of Glu266 (upper left), Oγ of
of Ala411 to the carboxylate on the right is not shown. Lower panel: the
the Shewanella FCc structure 1QJD (pastel blue) based on aligning 59 Cα
0.39 Å). Note the general similarity and the close superpositioning of the
Table 2
Approximate bonds and angles for TEO from the structures
1QJD 2H88a 2H88b Comment
Bond lengths
C1 O1A 1.178 1.259 1.263
C1 O1B 1.216 1.293 1.278
C2 O2 1.318 1.438 1.360 C–OH bond,
longer than C_O
C2 C1 1.601 1.630 1.699 single bond,
no resonance
C3 C2 1.376 1.332 1.376 double bond?
ene-ol?
C4 C3 1.369 1.504 1.492 resonance?
C4 O4A 1.323 1.258 1.262
C4 O4B 1.487 1.282 1.301
Bond angles
O1A C1 O1B 133.01 126.78 128.97
C2 C1 O1B 108.97 109.55 107.58
C2 C1 O1A 116.51 123.55 123.45
C1 C2 O2 114.66 104.20 102.69
C3 C2 O2 131.65 142.16 148.39
C1 C2 C3 109.09 113.47 108.86
C2 C3 C4 119.47 105.55 102.17
O4B C4 C3 120.59 125.60 127.42
O4A C4 C3 130.80 106.21 105.38
O4A C4 O4B 107.31 121.24 120.96
Dihedral angles
O4B C4 C3 C2 1.40 −179.42 177.59 C3–C4 dihedral
C3 C2 C1 O1A 89.52 57.93 61.59 C1–C2 dihedral,
measured to c3
O2 C2 C1 O1B 56.23 65.31 63.13 C1–C2 dihedral,
measured to O2
Improper dihedral angles
C4 O4A 04B C3 6.238 19.079 17.838 C4 Carboxylate
slightly dished?
C2 C3 C1 O2 11.648 −2.271 −1.232 C2 Center flat?
C1 C2 O1A O1B −7.287 2.371 −0.295 C1 Carbox flat
For each parameter, three values are given: one from Shewanella structure
1QJD, and one from each monomer of Complex II structure 2H88.
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position of that structure and the involvement of residues
equivalent to Arg408, His253, His364. The most significantFig. 4. Stereo view of malonate in the dicarboxylate site of Complex II. The prote
methods. Coordinates and 2Fo–Fc map from the structure deposited as 2H89. The vdifference is the involvement of the residue equivalent to
Arg297, which was disordered, in 1E7P. Refinement at zero
occupancy left it rather too far from the ligand to be involved
in binding.
3.3. Spectroscopic analysis of the state of the dicarboxylate site
It has long been known that binding of OAA and other
inhibitors is accompanied by subtle but distinct changes in the
spectrum of the enzyme. As an aid in characterizing different
batches of the enzyme and in studying binding at the
dicarboxylate site, we are obtaining spectra of the changes
induced by ligand binding. The OAA effect is taken as the
negative of the slow change occurring when OAA is removed
from the enzyme by treatment with transaminase and 10 mM L-
glutamate as described in the legend to Fig. 5. Raw difference
spectra from such an experiment are shown in Fig. 5A, in which
isobestic points suggest a single change is taking place. The
dissociation was fit well by a single exponential (Fig. 5B),
allowing extrapolation to infinite time to obtain the spectrum of
the unliganded enzyme. The reaction was repeated at different
temperatures and the Arrhenius plot (Fig. 5B inset) indicates an
activation energy of 25.4 kcal/mol, similar to the value obtained
by for activation of SDH by anions and pH [20], but lower than
the value (33 kcal/mol) found for activation by substrates or
ubiquinol [21]. In one case aspartate and α-ketoglutarate were
added to regenerate OAA after stripping was nearly complete,
and the immediate spectral change induced by rebinding of
OAA was indistinguishable from the slow change observed
during dissociation (but with greater extent). The same spectral
change was also observed (not shown) on treatment with
malate; in fact this treatment yielded the largest OAA-effect
spectrum, which we assume corresponds to 100% occupancy
with the tightly bound ligand. This is consistent with the
observation [7] that addition of malate to activated enzyme
leads to inactivation and tightly-bound OAA as assayed by
perchlorate extraction. Note that although we refer to this
spectral change as the “OAA effect”, the precise nature of the
bound ligand in the OAA-inhibited enzyme is still open to
question.in was crystallized in the presence of malonate. as described in Materials and
iew is nearly the same as in Fig. 3.
Fig. 5. (A) The spectral effect of OAA binding was determined by following the
dissociation of OAA from Complex II in the presence of OAA transaminase
scavaging system [5]. Complex II was diluted to 1 ml in buffer A supplemented
with 10 mM glutamate, and two initial spectra were recorded. Then 1 μ1 of
transaminase was added and scans were recorded repeatedly during the
stripping process. The average of the spectra of Complex II before adding
transaminase was subtracted from all, and spectra before and at 0, 6.8, 28.6,
43.4, and 66 min after the addition are plotted. Then (not shown) dithionite was
added to obtain the fully reduced spectrum from which the enzyme
concentration was determined. (B). Time course of dissociation of OAA. A
spectrum representative of the OAA-induced change was obtained form the
spectra of Fig. 4A. The experiment of (A) was repeated several times, and one
of these experiments, in which the decay was slightly faster, was selected for
determining the spectrum of the fully-stripped enzyme. The spectra were fit to a
linear combination of spectra of the as-purified Complex II and the OAA-
induced change. The resulting amplitude of the OAA effect was plotted against
time and fit with a single exponential. The t∞ value obtained from the fit was
taken as the amount of the OAA-effect spectrum to subtract from the as-purified
spectrum to obtain the spectrum of the fully-stripped enzyme, which was scaled
to 1 μM based on the concentration determined from the dithionite-reduced
spectrum above. The spectrum of the OAA effect was scaled by assuming the
site was fully occupied with OAA in the malate-treated enzyme. The spectra
were then re-fit using this normalized OAA effect spectrum and the stripped
Complex II spectrum, to obtain the data shown, in which the OAA effect
decays toward zero. The resulting value for Complex II concentration was
constant at 5.7 cM, and the OAA effect before adding transaminase was
2.4 μM. Inset: the experiment was repeated at different temperatures and the log
of the first-order rate constant was plotted against reciprocal temperature to
obtain an approximate activation energy of 25.4 kcal/mol (106 kJ/mol).
Fig. 6. Difference spectra representing the effects of various ligands on the
spectrum of fully oxidized Complex II. Preliminary standard spectra for the
spectral effects of OAA, malonate, fumarate, and 3-nitropropioninc acid were
determined as described in the text. The magnitude is on an arbitrary scale.
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acid were obtained by adding the ligands at appropriate
concentrations after nearly all the OAA was remove bytransamination. Our current set of standard spectra for the
ligand-induced changes is shown in Fig. 6. The effects of
fumarate, malonate, and 3-nitropropionate are similar but
distinguishable, and consistent with a perturbation of the
spectrum of oxidized flavin in that they do not extend to longer
wavelength than about 550 nm. The similarity of the
nitropropionate effect with those of fumarate and malonate
suggests that on this time scale (10–20 min) simple non-
covalent binding takes place, and the covalent modification
reported [16] requires longer incubation.
The effect of OAA binding is quite different, and involves
significant changes over the wavelength range up to 700 nm,
where oxidized flavin has little or no absorbance. This long-
wavelength absorbance change suggests a long range
structural perturbation that affects the iron–sulfur clusters,
or a redox effect involving iron–sulfur clusters or perhaps
flavin semiquinone.
3.4. Ligand-status of the protein sample from which the crystal
yielding the high-resolution TEO structure was prepared
As described above, attempts to replace OAA by fumarate
for crystallization led to a structure containing the malate-like
intermediate TEO in the dicarboxylate site. A portion of the
pooled fractions from the fumarate-containing density gradi-
ent was taken and the spectrum recorded with no further
treatments to evaluate the effectiveness of fumarate exchange.
As Fig. 7 shows, this spectrum could be fit well using the
spectrum of unliganded Complex II, the OAA effect, and the
fumarate effect. Of the latter, the OAA effect is much more
prominent, being present at a higher level relative to the
Complex II spectrum than in any of our untreated prepara-
tions to date. Only a preparation treated with malate showed a
higher level of the OAA effect, presumably due to the highly
spontaneous if kinetically limited oxidation of malate to OAA
by Complex II and any endogenous quinone. The molar
extinction scale of the OAA effect has been derived assuming
Fig. 7. Spectrum of Complex II after exchange into fumarate for crystallization.
The blue trace is an experimental spectrum of the Complex II preparation from
which the crystal leading to the 2H88 structure was grown. It had been treated
with malonate at room temperature for 3 h and sedimented through a gradient
containing 5 mM fumarate as described in Materials and methods. The green
trace is the best fit to the experimental trace using a linear combination of the
spectra of Complex II, the fumarate effect, and the OAA effect. The required
magnitude of each of these is shown (respectively light blue, magenta, and
brown).
Fig. 8. Time course of spectral changes after adding fumarate to Complex II.
About 5 mM Complex II in buffer a was monitored spectrally before and after
addition of 10 mM sodium fumarate. The temperature was 20 °C. (A). Time
course: each time point represents one spectrum. Fumarate was added after the
second spectrum (arrows). Each spectrum was fit to a linear combination of the
empty-site complex, the OAA effect, and the fumarate effect. The amount of
each spectrum required to reconstitute the experimental spectrum is plotted
against time. Panels B and C show (blue traces) difference spectra: 14 min vs.
before fumarate (B) and 460 min vs. 14 min (C). The green curves show the fit to
these two spectra and the red and magenta curves show the amount of the OAA
and fumarate spectral effects required to fit them. The slow phase (C) consists
mainly of disappearance of the fumarate effect and appearance of the OAA
effect, suggesting that fumarate is being converted into the tightly-bound ligand
of the OAA-inhibited complex.
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and applying this scale to the experiment of Fig. 7 indicates
that 78% of Complex II has OAA bound. Similarly the
amount of fumarate effect corresponds to 22% of Complex II
having fumarate bound. The fact that these add up to 100%
must be largely fortuitous, given the crude state of our
normalization, however it would in fact be expected that
nearly all sites would be occupied as the fumarate concentra-
tion (5 mM) is well above the Kd.
3.5. Apparent conversion of fumarate to OAA by the Complex
II preparation
To test more directly for conversion of fumarate to OAA, a
sample of Complex II from a preparation that happened to be
relatively depleted in OAA was treated with fumarate and
spectra were taken at intervals. The spectra were fit using
unliganded Complex II and the fumarate and OAA effects
from Fig. 6. The amount of each required is plotted in Fig.
8A as a function of time the spectrum was taken There is a
sharp increase in the fumarate effect immediately after
addition of fumarate, as expected. However the fumarate
effect soon levels off and starts to decrease. The OAA effect
was decreasing slightly during this time, perhaps due to re-
equilibration after dilution of the enzyme and competition
from the fumarate, but starts to increase again after about
20 min. The subsequent gradual increase mirrors the decrease
in the fumarate effect.
Difference spectra representative of the fast phase and slow
phase are shown in Fig. 8B and C, together with their
composition from the basis spectra. The fast phase consists
mainly of fumarate binding, and the slow phase consists of
replacement of the fumarate spectral effect by the OAA effect.This appears consistent with the idea that fumarate is being
converted to OAA.
4. Discussion
The experiment of Fig. 7, as well as the observation of TEO
in 2H88 from material treated with fumarate, suggests that long
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the enzyme as OAA or the endogenous inhibitor. This would
explain the observation that after activation by succinate the
enzyme eventually returns to a partially inactivated state,
whereas activation by malonate is stable for long periods of
time. It was reported [7] that fumarate or low concentrations of
succinate result in gradual deactivation of the activated enzyme,
which was attributed to formation of OAA as a result of
fumarase contamination and the MDH activity of Complex II.
We have not eliminated the possibility that contaminating
fumarase is responsible for the apparent conversion we see, but
the mechanism proposed by Taylor et al. for formation of the
malate-like intermediate [12] would also be a reasonable
explanation.
If we assume the same tightly bound ligand is present in the
inhibited enzyme obtained with fumarate or OAA, the next
question is, what is it? Covalently it has the structure of OAA
or malate. While we cannot rely too strongly on bond lengths
and angles obtained from X-ray diffraction at this resolution,
the data of Table 2 can suggest the geometry of the model. The
out-of-plane c1 carboxylate and long c1–c2 bond would be
consistent with malate or with a distorted OAA in which the
conjugation between the keto or enol double bond and the C1
carboxylate has been broken by the torsion. The long bond
from C2 to its attached oxygen would be more consistent with
–OH as in malate or the enol form of OAA than with a keto
group. The short C2–C3 and C3–C4 bonds would be
consistent with enol-OAA with the central double bond
conjugated with the C4 carboxylate. It would be also consistent
with the tautomer of malate depicted in Fig. 4B of Taylor et al.
[12].
In light of the MDH activity of the complex, and the
redox midpoint potential of the malate/OAA couple
(∼−166 mv in solution) relative to the Flavin, it would
seem that malate could not exist in the binding site with
oxidized flavin for long. However it cannot be assumed that
the redox potential of the bound malate/OAA couple is the
same as in solution. It is quite possible that malate is bound
very tightly as Taylor et al.'s tautomer, whereas oxaloacetate
is highly destabilized by enforced torsion around the C1–C2
bond, resulting in a much more positive midpoint potential
for the bound couple.
The main distinction between malate and OAA is their
reduction level. Formation of OAA from fumarate via malate, or
removal of malate after conversion to OAA, should involve an
oxidation step which would leave two electrons on the enzyme,
presumably residing in the high potential iron–sulfur centers 1
and 3. While the broad bleaching extending to 700 nm
associated with the stripping reaction (Fig. 4A) is suggestive
of reduction of iron–sulfur centers, the reverse spectrum is
obtained on adding OAA to (presumably oxidized) enzyme, in
which case it could not be an effect on redox state of the iron–
sulfur proteins. Further experiments with electron acceptors
(PMS/DCIP) and using transaminase to strip the enzyme after
loading from malate or OAA may help resolve the issue.
Although spectral studies indicate our preparation of
Complex II is less than half loaded with oxalaocetate, theexcellent density from the crystals gives no indication of partial
occupancy. Assuming occupancy of 1.0, the B-factors are
similar to those of the surrounding protein. Alternate refinement
of ligand occupancy and B-factors does not lead to decreased
occupancy. This suggests that the ligand-bound (OAA or
malonate) enzyme may preferentially crystallize in these crystal
forms. There is considerable reason to believe [2], other crystal
structures have suggested, and the tightly enclosed nature of the
bound ligand would seem to make it necessary, that a major
conformational change accompanies unbinding of the ligand.
However a crosslinking study of the Shewanella FCc failed to
demonstrate a requirement for mobility [22].
Our failure so far to obtain crystals of the empty-site or
NEM-treated enzyme under these conditions would be
consistent with preferential crystallization of the closed,
ligand-bound form. Examination of crystal contacts reveals
significant involvement of the CAP domain in each monomer of
the type 2 crystals, but not in the type one crystal form. Future
experiments will be aimed, on one hand, at trying to increase the
yield of crystals by loading the enzyme through malate
treatment, and on the other, at trying to obtain crystals of the
stripped enzyme. It is important to be able to study other
conformations crystallographically as well, even if it requires
developing new crystal forms.
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